- Home
- PBHC vs PLRX Comparison
PBHC vs PLRX Comparison
Compare PBHC & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PBHC | PLRX |
|---|---|---|
| Founded | 1859 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.9M | 93.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PBHC | PLRX |
|---|---|---|
| Price | $14.90 | $1.28 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $3.79 |
| AVG Volume (30 Days) | 3.5K | ★ 1.8M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.69% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.07 | N/A |
| Revenue | ★ $44,154,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.03 | ★ N/A |
| Revenue Growth | ★ 24.40 | N/A |
| 52 Week Low | $13.50 | $1.10 |
| 52 Week High | $17.92 | $15.27 |
Technical Indicators
Market Signals| Indicator | PBHC | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.04 | 33.20 |
| Support Level | $13.50 | $1.17 |
| Resistance Level | $14.95 | $1.67 |
| Average True Range (ATR) | 0.45 | 0.12 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 96.55 | 21.15 |
Price Performance
Historical ComparisonAbout PBHC Pathfinder Bancorp Inc. (MD)
Pathfinder Bancorp Inc is a holding company for Pathfinder Bank. The Pathfinder Bank is a commercial bank engaged in attracting deposits from the general public and investing such deposits, together with other sources of funds, in loans secured by residential real estate, commercial real estate, small business loans, and consumer loans. The bank invests a portion of its assets in debt securities issued by the United States Government and its agencies and sponsored enterprises, state and municipal obligations, corporate debt securities, mutual funds, and equity securities. The principal source of income is interest on loans and investment securities.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.